Cognitive enhancement? Exploring modafinil use in social context

Advances in Medical Sociology

Volumn 13, Issue , 2011, Pages 203-208

  Coveney, Catherine M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84876139081     PISSN: 10576290     EISSN: None     Source Type: Book Series    
DOI: 10.1108/S1057-6290(2011)0000013013     Document Type: Article

References (91)

1. Akrich, M. (1992). The description of technical objects. In: W. Bijker & J. Law (Eds.), Shaping technology/building society: Studies in sociotechnical change, (pp. 205-224). Cambridge, MA: MIT Press
2. BMA. (2007). Boosting your brainpower: ethical aspects of cognitive enhancements, A discussion paper from the BMA, November
3. Borup, M., Brown, N., Konrad, K., & Van Lente, H. (2006). The sociology of expectations in science and technology. Technology Analysis and Strategic Management, 18(3/4), 285-298 (Pubitemid 44083929)
4. Brown, N., & Michael, M. (2003). A sociology of expectations: Retrospecting prospects and prospecting reterospects. Technology Analysis and Strategic Management, 15(1), 3-18 (Pubitemid 36533586)
5. Busfield, J. (2010). A pill for every ill: Explaining the expansion in medicine use. Social Science & Medicine, 70(6), 934-941.
6. Butcher, J. (2003). Cognitive enhancement raises ethical concerns. The Lancet, 362, 132-133
7. Cahill, M. (2005). The ethical consequences of modafinil use. Penn Bioethics Journal, 1(1)
8. Cephalon. (2008). Patient information: Provigil Tablets, Prov-011. Cephalon, March 2008
9. Chan, S., & Harris, J. (2006). Cognitive regeneration or enhancement: The ethical issues. Regenerative Medicine, 1(3), 361-366
10. Chatterjie, A. (2006). The promise and predicament of cosmetic neurology. Journal of Medical Ethics, 32, 110-113
11. Chatterjie, A. (2009). Is it acceptable for people to take methylphenidate to enhance performance? No. BMJ, 338, b1956. doi: 10.1136/bmj.b1956 (published June 18, 2009)
12. Cheshire, W. P. (2008). The pharmacologically enhanced physician. Virtual Mentor, American Medical Society Journal of Ethics, 10(9), 594-598
13. Clarke, A. E., Fishman, J. R., Fosket, J. R., Mamo, L., & Shim, J. K. (2003). Biomedicalization: Technoscientific transformations of health, illness and US biomedicine. American Sociological Review, 68, 161-194
14. Conrad, P. (2007). The medicalisation of society. Baltimore, MD: Johns Hopkins University Press
15. Conrad, P., & Potter, D. (2004). Human growth hormones and the temptations of biomedical enhancement. Sociology of Health and Illness, 26(2), 184-215 (Pubitemid 38507305)
16. Coveney, C. M. (2010). Awakening expectations: Exploring social and ethical issues surrounding the medical and non-medical uses of cognition enhancing drugs in the UK. Ph.D. thesis, University of Nottingham
17. Coveney, C. M., Nerlich, B., & Martin, P. (2009). Modafinil in the media: Metaphors, medicalisation and the body. Social Science & Medicine, 68(3), 487-495
18. Daniels, N. (2000). Normal functioning and the treatment-enhancement distinction. Cambridge Quarterly of Healthcare Ethics, 9, 309-322
19. De Vries, R. G., Turner, L., Orfali, K., & Bosk, C. L. (2007). Social science and bioethics: Morality from the ground up. Clinical Ethics, 2, 33-35
20. Dees, R. H. (2004). Slippery slopes, wonder drugs, and cosmetic neurology: The neuroethics of enhancement. Neurology, 63, 951-952. (Pubitemid 39287898)
21. DTI. (2005). FORESIGHT: Drug futures 2025? Horizon scan. Commissioned by the Office of Science and Technology. London: Her Majesty's Stationery Office.
22. Elliott, C. (2003). Better than well: American medicine meets the American dream. New York, NY: W Norton & Co.
23. EMA. (2010). Questions and answers on the review of medicines containing modafinil, November 19, 2010, EMA/725532/2010, EMEA/H/A-31/1186.
24. Escohotado, A. (1999). A brief history of drugs: From the stone age to the stoned age. Rochester, VT: Park Street Press.
25. Esposito, M. F. (2005). Ethical implications of pharmacological enhancement of mood and cognition. Penn Bioethics Journal, 1(1), 1-4.
26. Farah, M. (2002). Emerging ethical issues in neuroscience. Nature Neuroscience, 5(11), 1123-1128.
27. Farah, M. (2005). Neuroethics: The practical and the philosophical. TRENDS in Cognitive Sciences, 9(1), 34-40. (Pubitemid 40091931)
28. Farah, M., Illes, J., Cook-Deegan, R., Gardner, H., Kandel, E., King, P., y Wolpe, P. R. (2004). Neurocognitive enhancement: What can we do and what should we do? Nature Reviews Neuroscience, 5, 421-425. (Pubitemid 38568502)
29. Flower, R. (2004). Lifestyle drugs: Pharmacology and the social agenda. TRENDS in pharmacological Sciences, 25(4), 182-185. (Pubitemid 38519908)
30. Forlini, C., & Racine, E. (2009). Autonomy and coercion in academic cognitive enhancement using methylphenidate: Perspectives of key stakeholders. Neuroethics, 2(3), 163-177.
31. Fukayama, F. (2002). Our posthuman future. London: Profile Books.
32. Gazzaniga, M. S. (2005). Smarter on drugs. Scientific American Mind, 16(October), 32-37.
33. Glannon, W. (2006). Neuroethics. Bioethics, 20(1), 37.
34. Glannon, W. (2008). Psychopharmacological enhancement. Neuroethics, 1, 45-54.
35. Gore, R. K., Webb, T. S., & Hermes, E. D. A. (2010). Fatigue and stimulant use in military fighter aircrew during combat operations. Aviation, Space, and Environmental Medicine, 81, 719-727.
36. Greely, H., Sahakian, B., Harris, J., Kessler, R. C., Gazzinga, M., Campbell, P., & Farah, M. (2008). Towards responsible use of cognitive-enhancing drugs by the healthy. Nature, 456, 702-705.
37. Haimes, E. (2002). What can the social sciences contribute to the study of ethics? Theoretical, empirical and substantive considerations. Bioethics, 16(2), 89-113. (Pubitemid 34285665)
38. Hall, W. D., & Lucke, J. C. (2010). The enhancement use of neuropharmaceuticals: More scepticism and caution needed. Addiction, 105(12), 2041-2043.
39. Harding, G., & Taylor, K. M. G. (1997). McPharmacy medicines. The Pharmaceutical Journal, 226(7130), 56. (Pubitemid 33630047)
40. Harris, J. (2009). Give students smart drugs on demand to aid study. THES, January 1, p. 10.
41. Hedgecoe, A. (2001). Ethical boundary work: Geneticization, philosophy and the social sciences. Medicine, Health Care and Philosophy, 4, 305-309.
42. Hyman, S. E. (2006). Improving our brains? BioSocieties, 1, 103-111.
43. Kelley, A., Webb, Catherine, C., Athy, J., Ley, S., & Gaydos, S. (2010). Cognition-enhancing drugs and their appropriateness for aviation and ground troops: A meta-analysis. Army Aeromedical Research Lab, Fort Rucker Al Warfighter Performance and Health Div, December 2010.
44. Kramer, P. (1993). Listening to prozac: A psychiatrist explores antidepressant drugs and the remaking of the self. New York, NY: Penguin.
45. Lakoff, A. (2005). Pharmaceutical reason: Knowledge and value in global psychiatry. New York: Cambridge University Press.
46. Lindsay, C. (2005). From the shadows: Users as designers, producers, marketers, distributors and technical support. In: N. Oudshorn & T. Pinch (Eds.), How users matter: The coconstruction of users and technology. New Bakersville: MIT Press.
47. Lupton, D. (1997). Consumerism, reflexivity and the medical encounter. Social Science & Medicine, 45(3), 373-381. (Pubitemid 27303557)
48. Maher, B. (2008). Poll results: Look who's doping. Nature, 452, 464-465.
49. Malacrida, C. (2004). Medicalization, ambivalence and social control: Mothers' descriptions of educators and ADD/ADHD. Health, 8(1), 61-80. (Pubitemid 38184098)
50. Marcus, SJ. (Ed.) (2002). Neuroethics: Mapping the field conference proceedings. New York, NY: The Dana Foundation.
51. Martin, E. (2006). The pharmaceutical person. BioSocieties, 1, 273-287.
52. Martin, P., & Ashcroft, R. (2005). Neuroscience, ethics and society: A review of the field. Background paper prepared for the 2005 Wellcome Trust Summer School on 'Neuroethics', September 2005.
53. Martin, P., Pickersgill, M., Coveney, C. M., & Williams, S. J. (in press). Pharmaceutical cognitive enhancement: Interrogating the ethics, addressing the issues. In: F. Fenter (Ed.), Augmented cognition. Lausanne: EPFL Press.
54. Morrison, M. (2008). Beyond the perils and promise of human enhancement: The social shaping of enhancement technologies. eSharp Issue 12: Technology and Humanity (Winter), 1-24.
55. Murphy, E., & Dingwall, R. (2003). Qualitative methods of health policy research (pp. 76-102). New York, NY: Aldine de Gruyter.
56. Müller, U., Steffenhagen, N., Regenthal, R., & Bublak, P. (2004). Effects of modafinil on working memory processes in humans. Psychopharmacology, 117(1-2), 161-169. (Pubitemid 40109926)
57. Outram, S. (2010). The use of methylphenidate among students: The future of enhancement? Journal of Medical Ethics, 36, 198-202.
58. Parens, E. (Ed.) (1998). Enhancing human traits: Ethical and social implications. Washington, DC: Georgetown University Press.
59. Pasquale, F. (2010). Cognition enhancing drugs: Can we say no? Bulletin of Science Technology Society, 30, 9. 10.1177/0270467609358113
60. Pieters, T., & Snelders, S. (2009). Psychotropic drug use: Between healing and enhancing the mind. Neuroethics, 2, 63-73.
61. Pigeau, R., Naitoh, P., Buguet, A., McCann, C., Baranski, J., Taylor, M., y Mack, I. (1995). Modafinil, d-amphetamine and placebo during 64 hours of sustained mental work. I. Effects on mood, fatigue, cognitive performance and body temperature. Journal of Sleep Research, 4, 212-228. (Pubitemid 26010119)
62. POST. (2007, June). Postnote - Better brains. Number 285.
63. Post, S. G. (2000). The concept of Alzheimer disease in a hypercognitive society. In: P. J. Whitehouse, K. Maurer & J. F. Ballenger (Eds.), Concepts of Alzheimer disease: Biological, clinical, and cultural perspectives (pp. 235-256). Baltimore, MD: Johns Hopkins University Press.
64. Potts, A., Gavey, N., Grace, V. M., & Vares, T. (2003). The downside of Viagra: Women's experiences and concerns. Sociology of Health and Illness, 25(7), 697-719. (Pubitemid 37533085)
65. President's Council on Bioethics. (2002, April). Distinguishing therapy and enhancement. Staff Working Paper 7.
66. Quednow, B. (2010). Ethics of neuroenhancement: A phantom debate. BioSocieties, 5, 153-156.
67. Randall, D. C., Shneerson, J. M., Plaha, K. K., & File, S. E. (2002). Modafinil affects mood, but not cognitive function, in healthy young volunteers. Human Psychopharmacology, 18(3), 163-173.
68. Repantis, D., Schlattmann, P., Laisney, O., & Heuser, I. (2010). Modafinil and methylphenidate for neuroenhancement in healthy individuals: A systematic review. Pharmacological Research, 62(3), 187-206.
69. Rose, N. (2007). The politics of life itself. Princeton, NJ; Oxford: Princeton University Press.
70. Russo, M. (2007). Recommendations for the ethical use of pharmacologic fatigue countermeasures in the U.S. military. Aviation, Space, and Environmental Medicine, 78(5), 119-127.
71. Sahakian, B., & Morein-Zamir, S. (2007). Professor's little helper. Nature, 450(7173), 1157-1159.
72. Sample, I. (2004, July 30). MoD researchers to report on military uses of Provigil. The Guardian.
73. Schermer, M., Bolt, I., et al. (2009). The future of psychopharmacological enhancements: Expectations and policies. Neuroethics, 2(2), 75-87.
74. Sharma, V. (2011, February 16). Pilot pill project, Pune Mirror. Retrieved from http://www.punemirror.in/article/2/ 201102162011021606331644587714a65/Pilot-pill-project. html
75. Singh, I. (2005). Will the real boy please behave: Dosing dilemmas for parents of boys with ADHD. American Journal of Bioethics, 5(3), 34-47. (Pubitemid 41653987)
76. Singh, I. (2007). Clinical implications of ethical concepts: Moral self-understandings in children taking methylphenidate for ADHD. Clinical Child Psychology and Psychiatry, 12(2), 167.
77. Stevenson, F. A., Leontowitsch, M., & Duggan, C. (2008). Over-the-counter medicines: Professional expertise and consumer discourses. Sociology of Health and Illness, 30(6), 913-928.
78. Synofzik, M. (2009). Ethically justified, clinically applicable criteria for physician decisionmaking in psychopharmacological enhancement. Neuroethics, 2(2), 89-102.
79. Tannsjo, T. (2009). Ought we to enhance our cognitive capacities? Bioethics, 23(7), 421-432.
80. Teter, C. J., McCabe, S. E., LaGrange, K., Cranford, J. A., & Boyd, C. J. (2006). Illicit use of specific prescription stimulants among college students: Prevalence, motives and routes of administration. Pharmacotherapy, 26(10), 1501-1510. (Pubitemid 44521735)
81. THES. (2009, January 1). Give students smart drugs on demand to aid study. THES, p. 10.
82. Turner, D., Robbins, T. W., Clark, L., Aron, A. R., Dowson, J., & Sahakian, B. (2003). Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology, 165(3), 260-269. (Pubitemid 36197601)
83. Weiner, K. (2010). Configuring users of cholesterol lowering foods: A review of biomedical discourse. Social Science & Medicine, 71(9), 1541-1547.
84. Wheeler, B. (2006, October 26). UK army tested 'stay awake' pills. BBC News online.
85. White, B. P., Becker-Blease, K. A., & Grace-Bishop, K. (2006). Stimulant medication use, misuse, and abuse in an undergraduate and graduate student sample. Journal of American College Health, 54(5), 261-268.
86. Wilkie, A., & Michael, M. (2009). Expectation and mobilisation: Enacting future users. Science, Technology, and Human Values, 34(4), 502-522.
87. Williams, S. J. (2011). The politics of sleep: Governing (un)consciousness in the late modern age. Basingstoke: Palgrave Macmillan.
88. Williams, S. J., & Martin, P. (2009). Correspondence: Risks and benefits may turn out to be finely balanced. Nature, 457, 532.
89. Williams, S. J., Martin, P. A., & Gabe, J. (2011). The pharmaceuticalisation of society? A framework for analysis. Sociology of Health & Illness, 33(5), 710-725.
90. Wolpe, P. (2002). Treatment, enhancement and the ethics of neurotherapeutics. Brain and Cognition, 50, 387-395.
91. Woolgar, S. (1991). Configuring the user. In: J. Law (Ed.), A sociology of monsters (pp. 57-102). London: Routledge.